Burkett Financial Services LLC Sells 122 Shares of Johnson & Johnson (NYSE:JNJ)

Burkett Financial Services LLC decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 3.1% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,781 shares of the company’s stock after selling 122 shares during the period. Johnson & Johnson comprises approximately 0.3% of Burkett Financial Services LLC’s holdings, making the stock its 29th largest position. Burkett Financial Services LLC’s holdings in Johnson & Johnson were worth $598,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. 4J Wealth Management LLC lifted its holdings in Johnson & Johnson by 2.2% in the fourth quarter. 4J Wealth Management LLC now owns 2,835 shares of the company’s stock worth $444,000 after purchasing an additional 62 shares during the period. My Personal CFO LLC lifted its holdings in Johnson & Johnson by 1.4% in the fourth quarter. My Personal CFO LLC now owns 4,550 shares of the company’s stock worth $713,000 after purchasing an additional 62 shares during the period. Eagle Strategies LLC lifted its holdings in Johnson & Johnson by 1.8% in the fourth quarter. Eagle Strategies LLC now owns 3,589 shares of the company’s stock worth $563,000 after purchasing an additional 63 shares during the period. Clearview Wealth Advisors LLC lifted its holdings in Johnson & Johnson by 1.5% in the fourth quarter. Clearview Wealth Advisors LLC now owns 4,373 shares of the company’s stock worth $685,000 after purchasing an additional 64 shares during the period. Finally, Brookmont Capital Management lifted its holdings in Johnson & Johnson by 0.4% in the fourth quarter. Brookmont Capital Management now owns 14,852 shares of the company’s stock worth $2,328,000 after purchasing an additional 64 shares during the period. Institutional investors own 69.55% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the stock. HSBC raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and upped their price target for the company from $169.00 to $170.00 in a report on Thursday, April 18th. Royal Bank of Canada reissued an “outperform” rating and issued a $175.00 price target on shares of Johnson & Johnson in a report on Monday. Morgan Stanley cut their price target on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a report on Wednesday, April 17th. Bank of America cut their price target on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a report on Wednesday, April 17th. Finally, The Goldman Sachs Group initiated coverage on shares of Johnson & Johnson in a research note on Thursday, May 30th. They set a “neutral” rating and a $160.00 price objective for the company. Eight equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $174.07.

Johnson & Johnson Stock Down 0.2 %

Shares of Johnson & Johnson stock opened at $145.65 on Wednesday. The stock has a market capitalization of $350.53 billion, a P/E ratio of 9.08, a PEG ratio of 2.43 and a beta of 0.53. The company has a quick ratio of 0.94, a current ratio of 1.17 and a debt-to-equity ratio of 0.36. The stock has a 50 day moving average price of $148.13 and a two-hundred day moving average price of $154.56. Johnson & Johnson has a 12-month low of $143.13 and a 12-month high of $175.97.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, beating the consensus estimate of $2.64 by $0.07. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. The company had revenue of $21.38 billion during the quarter, compared to analysts’ expectations of $21.39 billion. During the same period in the prior year, the business earned $2.68 earnings per share. Johnson & Johnson’s revenue for the quarter was up 2.3% compared to the same quarter last year. Equities analysts expect that Johnson & Johnson will post 10.63 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st were given a $1.24 dividend. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.19. This represents a $4.96 annualized dividend and a yield of 3.41%. The ex-dividend date was Monday, May 20th. Johnson & Johnson’s dividend payout ratio (DPR) is 30.92%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.